AX-0810, an experimental medication Proqr Therapeutics is developing for biliary atresia and another liver disease called primary sclerosing cholangitis (PSC), is about to enter clinical testing. Proqr recently announced that regulatory authorities in the European Union have given the go-ahead to launch a Phase 1 clinical trial to test AX-0810 in healthy volunteers. According to […] The post Potential biliary atresia treatment AX-0810 to enter clinical testing appeared first on Liver Diseas...
